Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in USD (TTM)27.10bn
- Net income in USD915.80m
- Incorporated1925
- Employees49.10k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.23bn | 683.12m | 26.86bn | 41.10k | 39.41 | 2.85 | 21.10 | 3.26 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Gartner Inc | 5.97bn | 797.23m | 32.58bn | 20.29k | 41.77 | 45.70 | 32.87 | 5.46 | 10.05 | 10.05 | 75.24 | 9.18 | 0.7915 | -- | 3.80 | 295,054.30 | 10.57 | 8.24 | 19.95 | 14.76 | 67.72 | 67.55 | 13.35 | 12.20 | -- | 13.10 | 0.7738 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
| Biogen Inc | 9.66bn | 1.17bn | 32.75bn | 7.57k | 28.11 | 2.15 | 19.29 | 3.39 | 8.00 | 8.00 | 66.40 | 104.48 | 0.3777 | 1.27 | 4.80 | 1,276,499.00 | 4.56 | 12.53 | 5.20 | 14.83 | 75.03 | 81.84 | 12.08 | 26.93 | 1.32 | 3.78 | 0.3007 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| DuPont de Nemours Inc | 11.98bn | 404.00m | 34.35bn | 24.00k | 94.05 | 1.46 | 21.42 | 2.87 | 0.8736 | 0.8126 | 27.12 | 56.41 | 0.3036 | 3.37 | 4.99 | 499,208.30 | 1.12 | 0.3709 | 1.24 | 0.468 | 35.15 | 35.69 | 3.70 | 1.97 | 1.61 | 6.24 | 0.2446 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
| Iqvia Holdings Inc | 15.07bn | 1.36bn | 39.92bn | 87.00k | 29.89 | 6.29 | 16.01 | 2.65 | 7.33 | 7.33 | 81.34 | 34.82 | 0.5761 | -- | 4.64 | 173,206.90 | 5.19 | 3.24 | 6.93 | 4.07 | 35.03 | 34.32 | 9.01 | 6.03 | -- | 3.19 | 0.6809 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Takeda Pharmaceutical Co Ltd (ADR) | 27.10bn | 915.80m | 42.11bn | 49.10k | 46.05 | 0.9061 | 7.60 | 1.55 | 0.2899 | 0.2899 | 8.63 | 14.73 | 0.2934 | 1.30 | 6.86 | -- | 0.9922 | 1.65 | 1.19 | 1.97 | 66.54 | 68.05 | 3.38 | 6.06 | 0.5831 | 2.20 | 0.3997 | -- | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | -- |
| Moderna Inc | 5.15bn | -5.97bn | 54.63bn | 5.60k | -- | 4.26 | -- | 10.60 | -15.66 | -15.66 | 13.51 | 33.46 | 0.2523 | 7.78 | 8.24 | 920,178.60 | -29.22 | 20.95 | -34.13 | 29.51 | 22.43 | -- | -115.82 | 32.10 | 3.91 | -- | 0.0429 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Data as of Jun 05 2024. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD
1.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 13.12m | 0.42% |
| Mondrian Investment Partners Ltd.as of 31 Mar 2024 | 12.08m | 0.38% |
| Parametric Portfolio Associates LLCas of 31 Mar 2024 | 4.27m | 0.14% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 3.12m | 0.10% |
| Brandes Investment Partners LPas of 31 Mar 2024 | 2.90m | 0.09% |
| Strategic Advisers LLCas of 31 Mar 2024 | 2.51m | 0.08% |
| Millennium Management LLCas of 31 Mar 2024 | 2.32m | 0.07% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 2.25m | 0.07% |
| Goldman Sachs Asset Management LPas of 31 Mar 2024 | 2.04m | 0.07% |
| Aperio Group LLCas of 31 Mar 2024 | 1.99m | 0.06% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
